Cyclopenta[d]pyrimidines and dihydropyrrolo[2,3-d]pyrimidines as potent and selective corticotropin-releasing factor 1 receptor antagonists

ChemMedChem

Volumn 2, Issue 4, 2007, Pages 528-540

  Arban, Roberto ^a   Benedetti, Roberto ^a   Bonanomi, Giorgio ^a   Capelli, Anna Maria ^a   Castiglioni, Emiliano ^a   Contini, Stefania ^a   Degiorgis, Fabio ^a   Di Felice, Pina ^b   Donati, Daniele ^a   Fazzolari, Elettra ^a   Gentile, Gabriella ^a   Marchionni, Chiara ^c   Marchioro, Carla ^a   Messina, Flavia ^c   Micheli, Fabrizio ^a   Oliosi, Beatrice ^a   Pavone, Francesca ^a   Pasquarello, Alessandra ^a   Perini, Benedetta ^a   Rinaldi, Marilisa ^a   Sabbatini, Fabio M ^a   Vitulli, Giovanni ^d   Zarantonello, Paola ^a   Di Fabio, Romano ^a   St Denis, Yves ^a   more..

^a GSK   (Italy)

^b PFIZER INC   (United States)

^c NERVIANO MEDICAL SCIENCES   (Italy)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antagonists; Corticotropin releasing factor; Drug design; Receptors; Structure activity relationships

Indexed keywords

ANXIOLYTIC AGENT; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 1; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; LIVER MICROSOME; METABOLISM; PROTEIN BINDING; RAT; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; VOCALIZATION;

ANIMALS; ANTI-ANXIETY AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP; VOCALIZATION, ANIMAL;

EID: 47549089311     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200600257     Document Type: Article

References (16)

1. a) J. Fawcett, R. L. Barkin, J. Clin. Psychiatry 1997, 58 Suppl. 6, 32-39;
2. b) C. L. DeVane, J. Clin. Psychiatry 2000, 61 Suppl. 11, 4-8.
3. W. Vale, J. Spiess, C. Rivier, J. Rivier, Science 1981, 213, 1394-1397.
4. For some reviews and opinions on the subject, see: a) P. J. Gilligan, Y.-W. Li, Curr. Opin. Drug Discovery Dev. 2004, 7, 487-497;
5. b) E. P. Zorrilla, G. F. Koob, Expert Opin. Invest. Drugs 2004, 13, 799-828.
6. D. W. Schulz, R. S. Mansbach, J. Sprouse, J. P. Braselton, J. Collins, M. Corman, A. Dunaiskis, S. Faraci, A. W. Schmidt, T. Seeger, P. Seymour, F. D. Tingley III, E. N. Winston, Y. L. Chen, J. Heym, Proc. Natl. Acad. Sci. USA 1996, 93, 10477-10482.
7. L. He, P. J. Gilligan, R. Zaczek, L. W. Fitzgerald, J. McElroy, H. S. Shen, J. A. Saye, N. H. Kalin, S. Shelton, D. Christ, G. Trainor, P. Hartig, J. Med. Chem. 2000, 43, 449-456.
8. J. Saunders, J. Williams, Prog. Med. Chem. 2003, 41, 195-247.
9. a) P. J. Gilligan, D. W. Robertson, R. Zaczek, J. Med. Chem. 2000, 43, 1641-1660;
10. b) J. R. McCarthy, S. C. Heinrichs, D. E. Grigoriadis, Annu. Rep. Med. Chem. 1999, 34, 11-20;
11. c) J. R. McCarthy, S. C. Heinrichs, D. E. Grigoriadis, Curr. Pharm. Des. 1999, 5, 289-315.
12. All pharmacophore modeling work was performed with Catalyst 4.5 (Accelrys Inc).
13. N. Zanatta, M. B. Fagundes, R. Ellensohn, M. Marques, H. G. Bonacorso, M. A. Martins, J. Heterocycl. Chem. 1998, 35, 451-455.
14. M. Hori, T. Kataoka, H. Shimizu, E. Imai, T. Iwamura, K. Maeda, Chem. Pharm. Bull. 1986, 34, 3599-3605.
15. R. G. Melik-Ogandzhanyan, G. G. Danagulyan, S. A. Fagradyan, V. S. Mirzoyan, V. M. Okhikyan, L. G. Alaverdova, R. V. Agababyan, L. G. Akopyan, S. A. Papoyan, Khim.-Farm. Zh. 1983, 17, 299-303.
16. C. R. Gardner, J. Pharmacol. Methods 1985, 14, 181-187.